Eastern Cooperative Oncology Group

东部肿瘤合作组

• 批准号: 7616144
• 负责人: thomas matthew habermann
• 金额: $ 23.19万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7616144
• 关键词: Agonist; Ancillary Study; Applications Grants; Area; Authorship; Award; Cancer Center; Clinic; Clinical; Clinical Research Associate; Clinical Trials; Community Clinical Oncology Program; Complement; Correlative Study; Databases; Development; Dexamethasone; Discipline of Nuclear Medicine; Disease; Disorder by Site; Doctor of Medicine; Dose; Eastern Cooperative Oncology Group; Evaluation; Faculty; Flow Cytometry; Follow-Up Studies; Goals; Grant; Growth and Development function; Hematologic Neoplasms; Hematology; Hematopathology; Human Resources; Immune response; Institution; Interferon Alfa-2b; Interleukin-12; Interleukin-2; Investigation; Laboratories; Laboratory Study; Maintenance Therapy; Malignant - descriptor; Malignant Neoplasms; Measures; Medical; Medical Oncology; Multiple Myeloma; National Cancer Institute; Newly Diagnosed; Nursing Faculty; Operative Surgical Procedures; Paper; Pathologist; Pathology; Patients; Phase; Phase II Clinical Trials; Phase III Clinical Trials; Prednisone; Principal Investigator; Prognostic Factor; Protocols documentation; Publications; Quality of Care; Radiation Oncology; Randomized; Regional Cancer; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Role; Stratification; System; Thalidomide; Treatment Protocols; Tumor Burden; Waldenstrom Macroglobulinemia; abstracting; angiogenesis; base; chemotherapy; design; high risk; improved; indexing; inhibitor/antagonist; lymph nodes; member; multicatalytic endopeptidase complex; patient population; primary amyloidosis of light chain type; programs; receptor; response; treatment program; trial comparing

DESCRIPTION (provided by applicant): The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group for 30 years. The purpose of this grant application is to support the continued membership of the Mayo Clinic in the Eastern Cooperative Oncology Group. The goals are directed toward a greater understanding of malignancies, a better understanding of related problems in malignant diseases, development of improved treatment programs in malignant diseases, and improved patient survival in malignant diseases. Mayo Clinic has the resources, personnel, facilities, and patient population to facilitate strong contributions to the research programs of ECOG. With the continued growth and development of the Mayo medical practice, we would anticipate significant protocol entry and scientific contributions. The ECOG affiliation with its strong treatment and ancillary laboratory programs which have evolved provide major benefits to Mayo Clinic, its investigators, its affiliated regional cancer programs, and the large group of patients with malignant diseases who are involved in these research activities. The specific aims of this grant proposal are to support the following aspects of Mayo Clinic ECOG research activities which include the following: 1.) evaluation of new protocol design and treatment regimens to provide group-wide ECOG Phase II and Phase III treatment protocols in malignant diseases; 2.) coordination of, and participation in, adjunctive laboratory-based correlative studies in association with ECOG treatment protocols in malignant diseases; 3.) development of new prognostic factors and indexes in hematologic malignancies; 4.) participation in disease-specific accrual and activities; 5.) and participation in administrative activities in ECOG. These aims will be incorporated into a clinical trial infrastructure that is focused on institutional patient quality of care, clinical research associate (CRA) development, and faculty development.

描述（由申请人提供）：梅奥诊所已成为东部肿瘤合作组织成员 30 年。 此项拨款申请的目的是支持梅奥诊所继续成为东部合作肿瘤学小组的成员。 目标旨在更好地了解恶性肿瘤、更好地了解恶性疾病的相关问题、制定改进的恶性疾病治疗方案以及提高恶性疾病患者的生存率。 梅奥诊所拥有资源、人员、设施和患者群体，可以为 ECOG 的研究项目做出强有力的贡献。 随着梅奥医疗实践的持续增长和发展，我们预计将产生重大的协议输入和科学贡献。 ECOG 的附属机构及其强大的治疗和辅助实验室项目不断发展，为梅奥诊所、​​其研究人员、其附属的区域癌症项目以及参与这些研究活动的大量恶性疾病患者提供了重大利益。 该拨款提案的具体目标是支持 Mayo Clinic ECOG 研究活动的以下方面，其中包括： 1.) 评估新方案设计和治疗方案，以提供全集团范围内的 ECOG II 期和 III 期恶性疾病治疗方案； 2.) 协调和参与与恶性疾病 ECOG 治疗方案相关的辅助实验室相关研究； 3.) 血液系统恶性肿瘤新的预后因素和指标的开发； 4.) 参与特定疾病的累积和活动； 5.) 并参与ECOG 的行政活动。 这些目标将纳入临床试验基础设施，重点关注机构患者护理质量、临床研究员 (CRA) 发展和教师发展。